Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MKRS - It should be noted that this is the most upbeat earnings release to day. I'm more excited than ever about this company. $4M record backlog should be noted as well as the fact that the ADEPT units are being very well received. If they get a product order, the stock will rocket.
That is the most upbeat earnings announcement I have read to date. I have never been more excited about this company.
bbotc/cramer - I don't think anyone listens to Cramer anymore when it comes to ETFC (or any other stock for that matter). He was pounding the table at $14 and again at $10 not so long ago.
ari/ETFC - I can see a gap up, in which case I would be thrilled. However, I don't anticipate any further major gaps down. Downward movement would be gradual at this point (unless they file BK, which won't happen for a while if they do IMO) which is why I have my stops.
Like SSK says, I could be wrong though.
ETFC buyout opinion
I personally don't think Ameritrade or Schwab will be a buyer. Instead, I'm guessing we'll see a buyout from the likes of Citigroup, Bank of America, Wells Fargo, or ING...each of which has either a lousy or non-existent trading platform.
It's certainly going to be interesting to see how this plays out. In the meantime, I'm holding on to my trade with tight stops.
r59/ETFC - Agreed.
Citi analyst has always had an agenda. Consider that Citi is a competitor and it's no surprise the negative bias far exceeded other analyst opinions.
This has made for a beautiful trade.
ETFC
I did. Bought in at $3.66. We'll see if it was bold or stupid. I'm expecting a double within 12 months.
Earnings
I have it in my notes that we will see earnings report today. Is that accurate? Lone analyst is expecting $0.22 earnings on 35.40M revs.
Biophage Pharma announces improved 2007 third quarter financial results
MONTREAL, Oct. 29 /CNW Telbec/ - Biophage Pharma Inc. (TSX: BUG.V), a
high-potential company focused on the development of innovative phage-based
products and technologies for the detection, prevention and control of
bacterial infections, reported today improved financial results for its third
quarter ended August 31, 2007.
Overview of Operations
Biophage reached an important milestone in its Biosensors Division in the
third quarter of 2007. The company launched the PDS(R) Biosensor at the
Nanotoxicity 2007 Trade show in Paris, France on June 27, 2007. This product
represents the first of many innovative biosensors in development by our
Biosensor Division. Biophage President and CEO, Dr. Mandeville, made a
presentation on the PDS(R) technology platform and the targeted markets for
this biosensor, which was designed for the rapid detection of toxicity
(predictive toxicity) of metals and nanoparticles.
The global demand for biosensors capable of rapidly detecting the toxic
effect of metals or nanoparticles on living human cells is exploding.
According to a recent BBC technical market research report, the U.S. in vitro
toxicity testing (predictive toxicity) market had a value of $765 million in
2006 and will double by 2011, reaching $1.5 billion. Biophage is well
positioned to capitalize on this rapidly expanding market by offering
companies and research laboratories a novel and efficient biosensor that can
rapidly screen large numbers of compounds for cell toxicity.
The PDS(R) Biosensor allows for the rapid and simultaneous screening of a
large number of toxic compounds, metals and nanoparticles and determines their
relative level of toxicity. It can also identify important parameters that
determine toxicity levels at various stages of development and manufacturing,
allowing companies to explore different strategies to circumvent potential
toxic effects or mitigate the risk to humans, animals and the environment. Our
targeted clients are government and regulatory agencies, research laboratories
and environmental investigators in the biopharmaceutical, agricultural,
cosmetics and probiotics fields.
In the Therapeutics Division, Biophage signed an important Memorandum of
Understanding (M.O.U.) with Hygie Canada of Longueuil, Quebec. Under the terms
of this M.O.U., both parties will engage in the development of an
environment-friendly system that utilizes naturally occurring phages in either
a liquid form or bound to plastic in order to reduce the incidence of
nosocomial infections. L'Hôpital du Sacré-Coeur de Montréal will play a key
role in this development.
Nosocomial infections (infections acquired in hospitals) are a major
cause of health-care complications, with important socio-economic impacts such
as prolonged hospital stays, increased mortality and morbidity and significant
increases in health costs. In North America, nosocomial infections are the
fourth leading cause of death. Since April 2003, several Quebec hospitals have
reported an increase in the incidence of morbidity and mortality resulting
from C. difficile infections. Nosocomial infections have become more prevalent
in the last few years with an alarming increase in bacterial superbugs, which
are resistant to antibiotics (for example Methicillin-Resistant Staphylococcus
Aureus (MRSA) infections).
Currently, in the fight against the propagation of nosocomial infections,
potentially toxic chemical agents are used for the decontamination of the
health-care environment. The use of these chemicals can have serious
repercussions as for example, chemical toxicity, development of bacterial
resistance and physical deterioration of treated surfaces. Natural products
such as phages have evolved to become a viable alternative for the prevention
and control of nosocomial infections. These phage-based products can also be
developed as therapeutic agents, covering the various levels of bacterial
contamination.
On August 28, 2007 Biophage Pharma announced the signing of a follow-on
contract with Alberta Agriculture and Food. As the direct result of a
successful pilot study (previously announced on April 3, 2007), Biophage and
Alberta Agriculture and Food have now entered into an agreement to proceed
with the production of large-scale volumes of highly purified bacteriophage
preparations in a fermentor. Securing this contract marks the beginning of a
new business opportunity for Biophage and strengthens its relationship with
Alberta Agriculture and Food. The completion of this second contract will
bring Biophage in a position to offer biotech companies working in this field,
as well as food producers and distributors, the commercial volumes of
bacteriophages required to prevent bacterial contaminations throughout the
supply chain, from the farm field to packaged products on store shelves.
Since the landmark U.S. Food and Drug Administration ruling of August
2006 allowing the use of phage preparations on ready-to-use-meat and poultry
products, Biophage has received several inquiries from food producers and
distributors who recognize the commercial potential of this innovative, safe
and environmentally friendly solution for the control of bacterial
contaminations.
Financial Results
Contract revenues for the three months ended August 31, 2007 amounted to
$148,587 compared with $184,311 in the same three month period in fiscal 2006.
The decrease in substantially attributable to the completion of significant
projects with important clients and slightly lower revenues from Beryllium
(BeLPT) testing, although partially offset by an increase in revenues
generated from MELISA(R) testing. Contract revenue for the nine months ended
August 31, 2007 amounted to $434,681, compared to $604,834 for the nine months
ended August 31, 2006.
Research and development ("R&D") costs for the three months ended
August 31, 2007 (before tax credits) amounted to $143,337, representing an
increase of $27,167, or 23%, over the $116,170 recorded in the same interim
period in the preceding fiscal year. The increase is substantially
attributable to the hiring of additional staff affected to R&D. R&D tax
credits for the third quarter amounted to $68,983, including a $30,000
provision for the interim period (21% of the R&D costs recorded in the three
months ended August 31, 2007) and $38,983 from a favorable assessment and
refund received in early June 2007 in regards to the previous fiscal year's
provisioned R&D tax credits. This compares to a $20,000 provision for the
three month period ended August 31, 2006, which represented 17% of the R&D
costs recorded in the third quarter of fiscal 2006. For the nine months ended
August 31, 2007, R&D costs totaled $409,538, representing a $115,381, or 39%
increase over the $294,157 recorded in the equivalent nine-month interim
period in the previous fiscal year, whereby the increase is also attributable
to additional staff and efforts towards R&D.
Costs of contracts for the three months ended August 31, 2007 amounted to
$98,385, some $31,794, or 24% lower than the $130,179 incurred during the same
period in the preceding fiscal year. The decrease is principally attributable
to lower laboratory supplies and office expenses (commensurate with the
decline in contract revenue between the two interim periods) as well as to the
departure of an employee in the contract services laboratory. For the nine
months ended August 31, 2007, costs of contracts amounted to $340,872,
representing a $21,882 decrease from the $362,754 recorded in the comparable
period in 2006, which decline is principally attributable to lower laboratory
supplies and office expenses.
General and administrative expenses totalled $111,237 for the three
months ended August 31, 2007, representing a decrease of $67,962, or 38%,
compared to the $179,199 for the three month period ended August 31, 2006. The
decrease is principally attributable to a decrease in professional fees
incurred during the interim period compared to that of the corresponding three
month period in fiscal 2006. For the nine months ended August 31, 2007,
general and administrative expenses totalled $445,553, representing a $73,620,
or 14% decrease relative to the $519,173 incurred in the corresponding
nine-month period in fiscal 2006, whereby the decrease is also principally
attributable to lower professional fees incurred in the period.
Biophage's net loss for the three month period ended August 31, 2007
amounted to $187,759 ($0.00 per share) compared to a net loss of $239,779
($0.01 per share) for the corresponding three month period in the preceding
fiscal year. The improvement is attributable to lower general and
administrative expenses, to the favorable assessment and refund received in
early June 2007 in regards to the fiscal 2006 provisioned R&D tax credits and
to the lower costs of contracts, although partially offset by lower contract
revenues, increased R&D efforts and the write-down of certain patents during
the interim period. The net loss for the nine months ended on August 31, 2007
amounted to $801,097, compared to a loss of $567,580 for the corresponding
nine-month period in fiscal 2006.
Liquidity and Financial Resources
As at August 31, 2007 Biophage had cash and cash equivalents of $155,578
compared to $214,344 at November 30, 2006. The decrease in cash and cash
equivalents from November 30, 2006 levels is substantially attributable cash
used in operating activities (after changes in non-cash working capital items)
and the repayment of the R&D tax credits-related loan, although partially
offset by cash received through the private placements completed during the
nine month period) as well as the loan secured with Investment Quebec ("IQ")
as described below.
During December 2006 and February 2007, the Corporation issued
4,045,458 units through private placement. Each unit is made up of one common
share and one common share purchase warrant, with each such warrant
exercisable for a period of two years at an exercise price of $0.17 per common
share. The 4,045,458 units were issued for a total cash consideration of
$525,910.
In early June 2007, the Corporation received its tax credits refund in
relation to research and development expenses incurred in fiscal 2006. The
refund was used to repay the Corporation's short term debt in its entirety
($100,000 as at May 31, 2007), which loan had been contracted to finance said
tax credits.
On July 16, 2007, the Corporation announced that its wholly-owned
subsidiary, Biophage Inc., had secured a $550,000 loan facility from IQ
payable in instalments. On July 16, 2007, a first instalment of $150,000 was
made and 38,181 warrants were issued to IQ. On September 19, 2007 and
October 15, 2007, a second and third instalment of $50,000 each were
respectively made to the Corporation under its loan facility with IQ. Pursuant
to their agreement, the Corporation issued 11,400 warrants and 12,396 warrants
to IQ in connection to the second and third instalments, respectively.
More detailed information regarding the foregoing can be found in the
interim unaudited consolidated financial statements and related management
discussion and analysis which have been filed today on SEDAR at www.sedar.com.
About Biophage Pharma Inc.
Biophage is a Canadian biotechnology company focused on the development
of innovative phage-based products and technologies for the detection,
prevention and control of bacterial infections. Biophage operates three
divisions: (1) The Immunotox Labs division, which provides services in
Immunogenicity and Immunotoxicity, Beryllium sensitivity testing (BeLPT) and
exclusive MELISA(R) testing for the detection of sensitization to more than
200 different allergens including metals, penicillin, gluten, pollens and more
recently Lyme disease (Boreliosis); (2) The Biosensors division for the
development and commercialization of Biosensors PDS(R); and (3) The
Therapeutics division for the prevention and control of bacterial
contaminations in the medical, veterinary and environment fields. Both the
Biosensor and Phage therapy programs have been structured to deliver an
environmentally safe solution for the early detection and rapid control of
deadly microorganisms.
(www.biophagepharma.net; www.immunotoxlabs.com).
CXPO/$9.60 - I'm in with starter position
MKRS - Current Events / ADEPT - Posted today at the website
November 2007 - Mikros Visits the USS San Jacinto in Norfolk, VA
On November 1, 2007, Thomas Meaney, President of Mikros Systems, and Mark Laureigh, the Applications Engineer for ADEPT® , visited the USS San Jacinto based at the Norfolk Naval Base, in Norfolk, VA. They met with a number of officers and SPY-1 radar technicians to review the test results of the ADEPT equipment that has been on the ship for the past 12 months.
The acceptance of the equipment was unanimous and one officer suggested that a cruiser of this type could utilize 3 equipments to properly cover all of the tasks to be accomplished in the maintenance of the radar.
Mikros thanked the ships crew for the professional evaluation of the equipment. The Surface Forces personnel in Norfolk encouraged Mikros to try to provide this type of equipment not only for the SPY-1 radar, but also for the other electronic equipment on the ship.
To date, ADEPT has been tested on the USS Philippine Sea, USS Bunker Hill, USS San Jacinto, as well as a number of land based test sites.
Derma Sciences Licenses Novel Angiotensin Analog Technology for Use in Wound Healing, Scar Reduction and Burns from the University of Southern California
Monday November 5, 7:00 am ET
Biologically Active Compound Shown to Promote Tissue Regeneration Will Initially Target Diabetic Ulcers and Scars Resulting from Surgical Procedures
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences (OTCBB: DSCI - News), a manufacturer and marketer of advanced wound care products, today announced it has acquired a global exclusive licensing contract for DSC127, a topical application for the treatment of wounds – such as diabetic ulcers, leg ulcers associated with venous insufficiency, pressure ulcers, and burns – as well as for the reduction of scars resulting from surgical procedures.
The patented compound, an angiotensin analog, was licensed from the University of Southern California. DSC127 has shown strong efficacy in National Institutes of Health (NIH) funded pre-clinical animal models in both accelerated healing of excisional injuries in diabetic animals as well as reduction of scars. An Investigational New Drug (IND) was granted by the FDA in July, 2006, and the product has recently completed its Phase I clinical program. The Phase II safety and efficacy clinical program is expected to begin in the first half of 2008 and be completed by the second half of 2009. This will be an important milestone in that it will show proof of principal in human disease.
Derma Sciences acquired the technology license for an $840 thousand up front payment, with certain milestone payments to USC based on regulatory and sales milestones, and royalties based on annual sales. The license includes a commitment on the part of Derma Sciences to develop the product, contributing an estimated $4-$5 million through Phase II. This will be defrayed in part by a continuation in NIH funding.
The markets for this product are large and growing. There are an estimated 2.4 million diabetic foot ulcers and over 60,000 diabetes related amputations each year. In 2001, the financial costs to US healthcare payers for the management of diabetic ulcers and their associated amputations were over $10 billion. There is currently only one FDA approved product available today for the treatment of diabetic ulcers, and its sales are approximately $100 million per year. With regard to the market for scar reduction, there are over 22 million non-cosmetic surgical procedures and 1.9 million cosmetic surgeries per year. The number of cosmetic surgeries is growing at over 12% per year. The market for an FDA-approved scar reduction treatment could reach as high as $4 billion in the US alone. There are no FDA approved pharmaceutical treatments for these indications.
Speaking of the USC license, Edward J. Quilty, President and CEO of Derma Sciences, said, “This technology offers our company the opportunity to develop a product with blockbuster potential at a reasonably low expense threshold, and is another example of how Derma Sciences is implementing its two-pronged strategy; We are building our private label manufacturing business through organic growth and acquisitions, and are subsequently using the significant cash flow generated by this core business to fund the research, development and commercialization of progressively more sophisticated and higher margin Derma Sciences-branded advanced wound care products.”
Quilty continued, “We are in fact already delivering on this strategy. Last year we successfully launched ALGICELL Ag™, an antimicrobial silver alginate dressing. Sales of this product have steadily grown quarter-to-quarter, and we closed out October with our best month yet with sales topping the $100 thousand mark. October was also a significant month in that we launched our MEDIHONEY™ line of Active Leptospermum Honey-based wound care dressings, and in the next six months we will launch our novel MOBILITY1™ intermittent pneumatic compression device for vascular therapy treatment.”
“At the same time, we are building a sales force to support our strategic vision. This is significant relative to DSC127 in that it will allow us to sell the product with our own direct sales force, as opposed to settling for much lower royalty-based revenues as many smaller technology companies do. This strategy will provide the greatest amount of value to Derma’s shareholders.”
Derma Sciences also announced that it has retained as its Chief Scientific Advisor, Laura Bolton, Ph.D, whose involvement in wound care began in 1974 for Johnson & Johnson where as Senior Scientist she evaluated such technologies as growth factors, and continued as Global Director of Scientific Affairs at ConvaTec, a Bristol-Myers Squibb company, where she was a pioneer in the development of hydrocolloids – one of the most significant categories of dressings in advanced wound care. She currently serves as Adjunct Associate Professor in the Department of Surgery at the University of Medicine & Dentistry of New Jersey, and has published more than 100 articles in peer-reviewed wound journals. Honored with the Sharon Baranoski Founder's Award at the 16th Annual Clinical Symposium for Advances in Skin Care and Wound Care for a career of mentoring and educating colleagues in wound care, Dr. Bolton is an acknowledged expert in the wound care field.
Speaking about the activity of the technology, Dr. Bolton said, “The biological effects of DSC127 seem well researched and sound. If the clinical studies match the pre-clinical results, the products from this technology have major potential in soft tissue and bone healing, dermatologic, surgical and oncologic applications. This molecule has passed rigorous testing with more promise than I have seen for any other active wound healing agent.”
Peer reviewed articles on the technology as applied to wound healing and scar reduction have appeared in such journals as the Journal of Peptide Research, Wound Repair and Regeneration, Experimental Dermatology, Plastic and Reconstructive Surgery, the Annals of Plastic Surgery, and the Journal of Burn Care and Rehabilitation.
About Derma Sciences:
Derma Sciences is a manufacturer and marketer of advanced wound care products, with operations based in the US and Canada, and sales worldwide. The company sources Active Manuka (Leptospermum scoparium) Honey from Comvita New Zealand, Ltd. Comvita controls over 70% of the flow of manuka honey, and owns several patents around the use of honey in wound dressings. The Company has also obtained FDA clearance to market and sell its MOBILITY-1™ boot and compressor device for the treatment of venous ulcers, lymphedema, and other conditions that require compression therapy. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.
About the USC Stevens Institute for Innovation
The USC Stevens Institute for Innovation (http://stevens.usc.edu) is a university-wide resource in the Office of the Provost at the University of Southern California designed to harness and advance the creative thinking and breakthrough research from USC for societal impact. USC Stevens identifies, nurtures, protects, and transfers to the market the most exciting innovations from USC, and in turn, provides a central connection for industry seeking cutting-edge innovations in which to invest. Furthermore, USC Stevens develops the innovator as well as innovations, through educational programs, community-building events, and showcase opportunities. From the biosciences and technology to music and cinematic arts, USC Stevens connects faculty, students, and the business community to create an environment for stimulating and inspiring the process of innovation across all disciplines. USC Stevens was established through a generous $22M naming gift from USC alumnus and trustee Mark A. Stevens, a partner at the legendary Sequoia Capital venture capital firm, and his wife, Mary.
Oil Contest: $85
Does anyone here follow Vioquest Pharma (VQPH.OB)?
If so, any opinion on their current clinical programs targeting oncology and infectious diseases?
Another big volume day. Was that 100k block trade a buy or a sell?
PDGE.OB breaking out
Doucet escalates efforts at Global Aircraft
Oct 23, 2007
Activist fund Doucet Asset Management LLC on Tuesday stepped up its efforts at aircraft maintenance and repair provider Global Aircraft Solutions Inc.
According to a Schedule 13D filing with the Securities and Exchange Commission, Doucet Asset Management wants to see Global Aicraft Solutions consider strategic alternatives, partnerships and add “depth” to its board. The activist fund reported owning a 5.124% stake in the $27.24 million stock market capitalization company. Perhaps expecting problems and delays, the activist fund is also asking Global Aircraft Solutions to set a date for its annual meeting.
Doucet’s efforts follow a June 1 activist SEC filing where the fund reported that it considered Global Aircraft Solutions undervalued and simply wanted to see the Tucson, Ariz.-based company’s management explore ways to “maximize stockholder value.” Apparently, from Doucet’s perspective, the company didn’t take appropriate steps in the intermediary four months.
Global Aircraft Solutions provides aircraft maintenance, repair and overhaul services for jet aircrafts. — Ron Orol
Ron Orol is a Washington-based reporter for The Deal and author of Extreme Value Hedging: How Activist Hedge Fund Managers Are Taking on the World.
PDGE Awarded Reconstruction Contracts Worth $12.3 Million
Tuesday October 23, 8:00 am ET
PITTSBURGH--(BUSINESS WIRE)--PDG Environmental, Inc. (OTC BB: PDGE - News), a leading provider of environmental remediation and specialty contracting services, today announced that it has recently been awarded reconstruction contracts valued, in aggregate, at $12.3 million. The projects, to be completed by June, 2008, include a $7.6 million restoration project for multi-family complexes in Texas as well as reconstruction work for commercial space, educational institutions, apartment complexes, and medical facilities in Illinois, Nevada, Texas, and Mississippi.
“We continue to see an increase in demand for reconstruction work nationwide, with the Company building a healthy backlog of such services for the fourth quarter of fiscal 2008 and first quarter of fiscal 2009,” said John Regan, chairman and chief executive officer. “Even with no impact from hurricanes this season, the Company’s core restoration/reconstruction business continues to grow.”
About PDG Environmental
PDG Environmental, Inc., headquartered in Pittsburgh, PA, is a leading provider of specialty contracting services including asbestos abatement, mold remediation, emergency response, demolition and reconstruction to commercial, industrial and governmental clients nationwide. With over twenty years experience, PDG Environmental has offices nationwide capable of responding to customer requirements coast to coast. For additional information, please visit http://www.pdge.com.
PDGE Awarded Reconstruction Contracts Worth $12.3 Million
Tuesday October 23, 8:00 am ET
PITTSBURGH--(BUSINESS WIRE)--PDG Environmental, Inc. (OTC BB: PDGE - News), a leading provider of environmental remediation and specialty contracting services, today announced that it has recently been awarded reconstruction contracts valued, in aggregate, at $12.3 million. The projects, to be completed by June, 2008, include a $7.6 million restoration project for multi-family complexes in Texas as well as reconstruction work for commercial space, educational institutions, apartment complexes, and medical facilities in Illinois, Nevada, Texas, and Mississippi.
“We continue to see an increase in demand for reconstruction work nationwide, with the Company building a healthy backlog of such services for the fourth quarter of fiscal 2008 and first quarter of fiscal 2009,” said John Regan, chairman and chief executive officer. “Even with no impact from hurricanes this season, the Company’s core restoration/reconstruction business continues to grow.”
About PDG Environmental
PDG Environmental, Inc., headquartered in Pittsburgh, PA, is a leading provider of specialty contracting services including asbestos abatement, mold remediation, emergency response, demolition and reconstruction to commercial, industrial and governmental clients nationwide. With over twenty years experience, PDG Environmental has offices nationwide capable of responding to customer requirements coast to coast. For additional information, please visit http://www.pdge.com.
Zen/DSCI - I picked up a starter position in DSCI today.
Nov 25 at midnight.
Qualmark Announces Appointment of Vice President of Sales and Marketing
Thursday October 18, 2:08 pm ET
DENVER, CO--(MARKET WIRE)--Oct 18, 2007 -- Qualmark Corporation (OTC BB:QMRK.OB - News), a world leader in designing, manufacturing and marketing HALT (Highly Accelerated Life Testing), HASS (Highly Accelerated Stress Screening) and electro-dynamic systems, today announced the appointment of Gary Larson as its Vice President of Sales and Marketing.
Mr. Larson has over 29 years of senior executive experience in business development and sales and marketing. Mr. Larson assumes his new post after holding several senior sales and marketing positions in the technology and electronics industry. He was most recently with Jing Mei Industrial, a Hong Kong-based company specializing in injection molded plastics, electroplating and thin-film coatings. He has also worked for Vapor Technologies, Philips Electronics and Iomega Corporation.
Charles Johnston, CEO and President, stated, "We are very pleased with Mr. Larson's decision to join Qualmark as we continue to penetrate new markets. To fill this role, we were looking for a candidate with a combination of attributes, including great technical depth, a solid track record of sales and marketing in the technology field with a strong base of personal contacts and industry knowledge. Gary is a remarkable fit for us, possessing the assets, skills and talents we were searching for. He will be a great resource for both Qualmark and for our partners alike."
Qualmark Corporation, headquartered in Denver, Colorado, is the leader in designing, marketing, and manufacturing accelerated life-testing systems (HALT and HASS) providing the world's largest corporations with solutions that improve product reliability and allow them to get to market faster. The Company has installed more than 600 of its proprietary testing systems in 30 countries. The Company operates and partners with ten testing facilities worldwide.
The Company also offers electrodynamic vibration solutions through its subsidiary, Ling Electronics.
Ling Electronics, headquartered in West Haven, Connecticut, is the leader in supplying electro-dynamic systems, components, and service to the worldwide vibration test equipment market.
ONT offers 13M shares at $1.00
On2 Technologies, Inc. Announces Common Stock Offering
October 18, 2007: 08:00 AM EST
TARRYTOWN, N.Y., Oct. 18 /PRNewswire-FirstCall/ -- On2 Technologies, Inc. announced today that it has agreed to sell 13,000,000 shares of its common stock in an underwritten public offering. Pursuant to the terms of the underwriting agreement, the shares will be offered to the public at a price per share of $1.00. The Company also granted the underwriters a 30-day option to purchase up to an additional 1,950,000 shares to cover over- allotments. All of the shares are being offered by the Company.
ThinkEquity Partners LLC is acting as the lead manager for the offering and Merriman Curhan Ford & Co. is acting as a co-manager.
The securities will be offered and issued pursuant to the Company's existing shelf registration statement on Form S-3, as amended and supplemented. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
This offering of shares of common stock may be made only by means of a prospectus supplement and accompanying prospectus. Copies of the prospectus supplement and the accompanying prospectus, when available, can be obtained from the SEC's website at www.sec.gov.
MKRS - New contract award
October 2007 - Mikros Systems Awarded Contract through Space and Naval Warfare Systems Command (SPAWAR)
Mikros Systems Corporation is pleased to announce we have been awarded contract for SBIR, "Wave Energy Harvesting Buoy for Communications at Speed and Depth and Distributed Sensor Networks". The contract, finalized October 11, 2007 with SPAWAR, was in response to the DoD Program Solicitation 2007.2 Topic No. N07-144 entitled "Small Buoy for Energy Harvesting".
FKLT: 1 Billion shares outstanding??? A 1:20 reverse split might be in order.
I don't think I could handle the anticipation
Yes, undervalued here IMO. Expecting some positive news soon. Any kind of PR should move this back up to $0.70 - $1 range. Of course a Navy product contract would take us much higher.
Len:
Thanks....and thanks for the insight
Len:
I looked through these, but HNSN is missing (probably due to the HDSN confusion). I have $23.82 as starting price, but wanted to make sure I had it right.
Thanks, Kris
Can I get the HNSN starting price and # shares?
Thanks.
nsomniyak challenge
MKRS.OB (KIK contest pick): Defense subcontractor. I'm expecting a production order from the Navy for their ADEPT system before end of year. I'm betting before end of PSL7. If/when it happens, this should go to $2 and win the KIK contest.
AMLJ.OB: Amplifiers and satellite communications. Undervalued here. Recent Mica-tech order goes a long way to validating that majority stake. Expecting new orders to take this back to $1.50 range during PSL7.
HNSN (Wild Card): Medical robotics company. Take a look at the stock chart for Intuitive Surgical (ISRG). Hansen Medical is the new gig for the founders of ISRG. I'm expecting a similar chart over the next several years. This pick may be a bit early, but the first sales came in the most recent quarter, so maybe not.
VDSI: Banking security company that is growing at an impressive clip. It's a top 3 IBD stock and has tripled since I bought it last year. 90% of its revenue still comes from Europe/Asia, which means there is plenty of room to grow in North America. I can't wait for their next quarterly release.
SIMC: Multi-plant electronics contract manufacturer with impressive management. Paying down debt ahead of schedule. Stock should continue to perform well. Probably my most conservative pick.
Thanks. Thought I was going senile for a moment.
Wrong stock holding.
I thought I picked HNSN as my wild card, not HDSN. Since my 6 picks posting has been deleted, I can't determine if this was a mistake on my end or yours. If I did indeed say HDSN in my post, please trade it for HNSN.
Thanks.
Biophage reports that its PDS®-16 biosensor can determine cyanobacteria toxicity
08-14-2007
In vitro test results obtained in 24 hours versus 7 days in animal bioassay.
Montreal, August 14, 2007 - (TSX.V: BUG). Biophage Pharma Inc. (Biophage) is very pleased to announce that its PDS®-16 Biosensor can determine the toxic effects (predictive toxicity) of Cyanobacteria on living cells. Cyanotoxins provided by U.S. EPA (Environmental Protection Agency) were used to generate data demonstrating that this biosensor can detect toxins produced by Cyanobacteria in a vastly improved time frame.
Cyanobacterial toxins are a major determinant of health effects associated with ingestion of water contaminated by Cyanobacteria. Despite the growing awareness of this important issue, rapid and precise methodologies that can detect and quantify the effects of these toxins on living cells are still a major challenge. Actually, toxicity methods rely essentially on animal bioassay and take about 7 days to be completed. Our technology is an automated cell growth assay that is simple, easy to use and label-free allowing on-line monitoring of toxicity within 24 hours.
"At Biophage we are extremely pleased to announce that our recently launched PDS® -16 Biosensor system can be used for the detection of Cyanotoxins in fresh water. These results open completely new markets for our biosensors in assessing health risks associated with exposure to Cyanotoxins. Currently, the global market for water safety monitoring and purification represents a multi-billion dollar opportunity" stated Dr. Rosemonde Mandeville, President and CEO of Biophage Pharma Inc. "Cyanobacteria contamination of fresh water and marine environments worldwide indicate potential problems for widespread human and animal health risks. We believe that our PDS®-16 Biosensor could provide faster exposure assessment and long-term monitoring of our rivers and lakes," concluded Dr Mandeville.
Mikros Systems Corporation Announces Second SBIR Phase I This Year
Tuesday August 14, 11:45 am ET
PRINCETON, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Mikros Systems Corporation (OTC Bulletin Board: MKRS - News) announced today that it has been notified by the U.S. Navy's Space and Naval Warfare Command that Mikros has been selected for award of a Small Business Innovation Research Program for a communication buoy for ocean-based data acquisition and sensor systems.
The Company is teamed with Ocean Power Technologies, Inc., a leader in ocean powered buoys for the Department of Defense and commercial markets. The program is expected to commence this fall with a contract value of approximately $100,000. This product area has potential war-fighting applications for the U.S. Navy and Coast Guard, as well as commercial applications.
"This is a great opportunity to apply Mikros communications expertise in a new application environment," stated Thomas J. Meaney, President. "We look forward to working with another division of the United States Navy on this project."
I'm 90% invested......but it sure feels good to have VDSI in my portfolio. It's helping me stay green today.
ONT imploding
Where did everyone go? How low will we go? I'm looking for a good entry point. Looks like the $2 support isn't holding.
MKRS breaks $1
Len - YOu can cancel my freeze
of NVD.....for now
It's trading in the opposite direction of what I expected.
Thanks.